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Glioblastoma (GBM) is a primary neuroepithelial tumor of the central nervous system, characterized by an extremely aggressive
clinical phenotype. Patients with GBM have a poor prognosis and only 3–5% of them survive for more than 5 years. The
current GBM treatment standards include maximal resection followed by radiotherapy with concomitant and adjuvant therapies.
Despite these aggressive therapeutic regimens, the majority of patients suffer recurrence due to molecular heterogeneity of GBM.
Consequently, a number of potential diagnostic, prognostic, and predictive biomarkers have been investigated. Some of them, such
as IDH mutations, 1p19q deletion, MGMT promoter methylation, and EGFRvIII amplification are frequently tested in routine
clinical practice. With the development of sequencing technology, detailed characterization of GBM molecular signatures has
facilitated amore personalized therapeutic approach and contributed to the development of a new generation of anti-GBM therapies
such as molecular inhibitors targeting growth factor receptors, vaccines, antibody-based drug conjugates, and more recently
inhibitors blocking the immune checkpoints. In this article, we review the exciting progress towards elucidating the potential of
current and novel GBM biomarkers and discuss their implications for clinical practice.
1. Introduction
Glioblastoma (GBM) is a primary neuroepithelial tumor of
the central nervous system, characterized by an extremely
aggressive clinical phenotype that has arisen from inter-
and intrapatient genomic and histopathological diversity
(Figure 1; Table 1). GBM is the most common of malignant
primary brain tumors in adults. It accounts for 12% to 15% of
all intracranial tumors and about 50% of astrocytic tumors.
Patients with GBM have a poor prognosis of just 12–
15 months following standard therapy, with only 3–5% of
patients surviving up to 5 years after diagnosis [1, 2].Themost
favorable prognostic factors include younger age at diagnosis
(<50 years), a Karnofsky Performance Status of at least 70
points, and the tumor being located in a noneloquent area of
the brain [3]. The current GBM treatment standards include
maximal resection (complete resection is achieved extremely
rarely due to the diffusely infiltrative nature of these tumors)
followed by radiotherapy with concomitant and adjuvant
therapies, for example, temozolamide (TMZ). If there is pro-
gression, bevacizumab against circulating vascular endothe-
lial growth factor (VEGF) is widely used, more recently
also in combination with lomustine (CCNU) [4]. Despite
these aggressive therapeutic regimens themajority of patients
suffer recurrence due to the molecular heterogeneity of
GBM tumors and penetration of therapeutic agents through
the blood-brain barrier (BBB). Both of these factors affect
treatment response and prognosis leading to acquired tumor
resistance inGBMpatients. However, recent developments in
next-generation sequencing methods have led to identifica-
tion of specific molecular signatures of GBM that allow for
better understanding of the molecular pathogenesis of this
disease [5]. Consequently, a number of potential diagnostic,
prognostic, and predictive biomarkers have been proposed.
Diagnostic biomarkers enable more accurate tumor classifi-
cation; prognostic biomarkers inform about a likely cancer
outcome (e.g., disease recurrence, disease progression, and
overall survival) and predictive biomarkers facilitate patient
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Table 1: Molecular biomarkers in GBM.
p53 signalling altered in 87% MDM2 (amplification in 14%)
RTK/RAS/PI3 signalling altered in 88% PI3K (mutation in 15%)
RB signaling altered in 78% CDK4 (amplification in 18%)
management by helping to tailor the treatment strategy to
patient-specific biology. There are some molecular markers
still under evaluation, but several are commonly tested as part
of the routine clinical interrogation of GBM patients includ-
ing O6-methylguanine DNA methyltransferase (MGMT),
isocitrate dehydrogenase (IDH), epidermal growth factor
receptor (EGFR), VEGF, tumor suppressor protein TP53,
phosphatase and tensin homolog (PTEN), p16INK4a gene,
phospholipid metabolites, cancer stem cells, and recently
also imaging biomarkers (Table 2). Importantly, detailed
characterization of these molecular signatures has facilitated
amore personalized therapeutic approach and contributed to
the development of a new generation of anti-GBM therapies
such as small molecular inhibitors targeting growth factor
receptors, vaccines, antibody-based drug conjugates, and
more recently inhibitors blocking the immune checkpoints
[6].
The aim of this article is to review the exciting progress
towards elucidating the potential of diagnostic, prognostic,
and predictive biomarkers of GBM and discuss their impli-
cations for clinical practice.
2. Glioblastoma Multiforme: A New Look
Gliomas have historically been classified and treated accord-
ing to the World Health Organization (WHO) criteria,
which are determined by histopathological examination,
for example, nuclear atypia, cellular pleomorphism, mitotic
activity, vascular thrombosis, microvascular proliferation,
and necrosis [7]. In the official reclassification of Tumor
Types of the Central Nervous System, published by WHO
on May 9, 2016, the GBMs are listed in the group of diffuse
astrocytic and oligodendroglial tumors which reflect their
highly malignant behavior [8].
Clinically, most patients present de novo grade IV lesions
(primary GBMs), whereas only a small fraction of patients
(5–10%) show progression from less aggressive WHO grade
II diffuse astrocytomas and WHO grade III anaplastic astro-
cytomas (secondary GBMs) [9].
Medical onset and progression of primary GBMs vary
from those seen in secondary GBMs, with the latter being
typically diagnosed at a younger age (45 versus 62 years),
having longer clinical history (16.8 versus 6.3 months) and,
although they are histologically largely indistinguishable,
having a better prognosis in terms of survival (7.8 versus 4.7
months) [10].
Importantly, these two clinical presentations have dis-
tinct molecular signatures. For example, primary GBMs
frequently present amplification/mutations of the EGFR gene
(36–60% of primary and 8% of secondary tumors), PTEN
mutation (25% of primary versus 4% secondary tumors),
and CDKN2A-p16INK4a deletion (31–78% of primary versus
8% secondary tumors) [10]. Additionally, there are genetic
aberrations that are expressed more frequently in secondary
GBMs including TP53mutations (28%of primary versus 65%
of secondary tumors) [10], MGMT promoter methylation
(36% of primary versus 75% of secondary tumors) [11], and
IDH1 mutations (5% of primary versus 75% of secondary
tumors) [12]. While histopathological analysis of gliomas has
formed the basis of diagnosis and treatment up to this point,
the widespread implementation of sequencing and profiling
technologies has resulted in more comprehensive analysis of
the molecular aberrations underlying gliomagenesis, as well
as providing insights into their biological heterogeneity.
The more recent analysis of GBMs by The Cancer
Genome Atlas Research Network (TCGA) highlighted the
most frequent alterations in GBM genes, including amplifi-
cation of EGFR and platelet-derived growth factor receptor
alpha (PDGFRA); mutation of TP53, phosphatidylinositol-
4,5-bisphosphate 3-kinase A (PIK3CA), PTEN, IDH1, RB1,
and TERT promoter; and deletions of PTEN, CDKN2A/B,
and MGMT, as well as alterations in chromatin remodeling
genes. Based on these dominant gene expression patterns,
four transcriptional subclasses of GBMs have been identified:
classical, proneural, mesenchymal, and neural [13, 14]. Each
of these subtypes is associated with specific genetic and
epigenetic alterations. The classical subtype is characterized
by the loss of chromosome 10 and amplification of chro-
mosome 7 with coexisting EGFR amplification/mutation,
impaired level of proapoptotic proteins, mitogen-activated
protein kinase (MAPK), and Notch1 and Notch3 proteins
[14, 15]. The proneural variant is associated with PDGFRA,
CDK6, CDK4MET, and frequent IDH1mutations, activation
of the phosphatidylinositol 3-kinase (PI3K), and inhibition of
the translation repressor 4EBP1 [14].
Mesenchymal GBMs frequently show deletions and
silencing mutations of NF1 on chromosome 17q11.2 and
point mutations in PTEN, activation of MAPK pathway, and
downregulation of mammalian target of rapamycin (mTOR)
signaling.
Less is known about the neural tumors, which are charac-
terized by the expression of neurofilament light polypeptide,
synaptotagmin I, and overexpression of EGFR [16]. In terms
of prognosis, no difference was found between the classical,
mesenchymal, and neural subtypes. However, the proneural
subtype was associated with onset at a younger age and
prolonged survival time [14]. This has been attributed to
mutations in the IDH1 gene, which are exclusively linkedwith
the proneural phenotype and grade II/III of astrocytic and
oligodendroglial tumors (72–100%) along with secondary
glioblastomas (85%). While primary GBMs could be of any
subtype and mutations in IDH1 are rarely found in these
tumors (5%) [17].
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Figure 1: Glioblastoma characterization. (a) Axial contrast-enhan-
ced T1-weighted MR image shows a large enhancing mass in the left
temporal lobe in a 54-year-old woman diagnosed with GBM. (b, c)
GBM formalin-fixed paraffin-embedded sections stained for H&E
andEGFRvIII. (d) Frequent alterations in critical signaling pathways
found in GBM.
Classification and subclassification of GBMs is not always
easy. Recent studies analyzing expression signatures of sin-
gle cells within GBM samples showed substantial intratu-
moral heterogeneity of expression subclasses within each
tumor. Sattoriva et al. examined genome-wide somatic copy
number levels in 38 fragments derived from 11 patients
with GBM. Although the fragments from the same patient
shared a common gene profile, they displayed a significant
variety of copy number alterations that were present in
only a subset of fragments. Moreover, using gene expres-
sion arrays, they found that in 6 out of 10 cases the
fragments from the same tumor mass were classified into
at least 2 different GBM subgroups, which indicated that
tumor clones with different phenotypic profiles are present
within the same malignancy [18]. This may explain the
difficulties associated with oncologic biomarker validation
and contribute to an incorrect selection of patients for
targeted therapies, treatment failure, or drug resistance
[19].
Additionally, GBM exhibit heterogeneity at the cellular
level, with a small subpopulation of tumor cells harboring
stem-like properties. These GBM stem cells (GBSC) are
capable of self-renewal and differentiation into neuronal,
macroglial, and mixed neuronal/astroglial phenotypes [20].
Recent genome-wide transcriptional analysis identified two
phenotypically different subtypes of GBSC, namely, proneu-
ral and mesenchymal, which also correlate well with corre-
sponding proneural and mesenchymal signatures in GBMs
[21, 22]. Mesenchymal GBSC (35–40% of cases) similarly
to mesenchymal GBMs, display a more aggressive pheno-
type and are more resistant to radiation as compared to
proneural GBSC. Moreover, GBSC possess unique surface
markers (e.g., CD133, CD15, and ALD1A3) and modulate
characteristic signaling pathways to promote tumorigenesis
(e.g., hedgehog and Notch) [23]. Interestingly, these GBSC
have the ability to shift phenotypic features from one subtype
to anotherwhen put under increased cellular stress (e.g., radi-
ation treatment) [22–24] and transdifferentiate into tumor
microenvironment cells such as endothelial cells and peri-
cytes, providing more favorable conditions for GBM growth
[25].
3. A Highway to Hell: Molecular Pathways and
Genetic Aberrations Found in GBM
Tumor growth in GBM cells is facilitated by high expression
of cell surface membrane receptors that control the intra-
cellular signal transduction pathways regulating proliferation
and cell cycle abnormalities including an increase in DNA
repair proteins and abnormal cell death pathways [26, 27].
An integrated analysis of the genetic alterations, performed
by the TCGA research network, confirmed that the most
commonly disrupted signaling cascades in GBM include
changes in pathways related to receptor tyrosine kinase
(RTK) signaling through the RAS/MAPK (mitogen-activated
protein kinase) and PI3K/AKT/mTOR, along with the cell
cycle-regulating retinoblastoma (RB) tumor suppressor and
p53 pathways.
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Table 2: Major biomarkers relevant to the management of patients with glioblastoma.
Type of
biomarker
EGFR mutation/
amplification
MGMT promotor
methylation IDH1/IDH2 mutation Imaging Reference
Diagnostic
EGFRvIII highly
correlates with
glioma subtypes.
Real-time
monitoring via
typing of
microvesicles with
EGFR specific
RNA.
Help to distinguish true
progression and
pseudoprogression in
patients with newly
diagnosed GBM treated
with surgery followed by
radiochemotherapy.
Differentiate between
primary and secondary
GBM.
IDH-mutant diffuse
gliomas and
nonanaplastic reactive
gliosis distinction.
Detection of specific
molecular abnormalities.
For example, EGFRvIII,
MGMT promotor
methylation, and 2-HG
which correlates with IDH
mutation.
[9, 76, 112–
115, 118–
120, 131–
134]
Development
status +/under evaluation Under evaluation + +
Prognostic
Better prognosis
with
(i) EGFRvIII +
Ki64 20% or less,
(ii) EGFRvIII +
normal PTEN,
(iii) EGFRvIII +
methylated
MGMT promotor.
Better OS and PFS
(probably with IDH
mutations) in malignant
gliomas treated with
radio- and/or
chemotherapy.
Better OS and PFS
MRI: extent of tumor
edema and necrosis has
negative correlation with
OS.
PET: 11C-MET uptake is
associated with poorer
patient survival.
[32–
36, 43, 44,
76, 78, 83,
85, 93, 126,
135–140]
Development
status +/under evaluation + + Under evaluation
Predictive
Possible biomarker
for vaccine-based
treatment.
Predicts response to
chemotherapy with
alkylation agents and
radiotherapy.
Correlate with better
response to TMZ in
(i) newly diagnosed
GBM with TMZ as a
first-line treatment,
(ii) recurrent GBM,
(iii) elderly patients.
IDH1 mutation is
independently
associated with
complete resection in
patients with malignant
gliomas treated with
surgery.
Complete surgical
resection is associated
with improved survival
in patients with IDH1
mutation.
Absence of mutation
suggests predictive role
of MGMT promotor
methylation for PFS in
patients treated with
chemotherapy.
Functional Diffusion
Maps (fDMs) predicts PFS
and OS in patients treated
with radiochemotherapy.
ADC predicts better
response to bevacizumab
combined with
chemotherapy.
Association between
hypoxia level (measured
by 18F-FIMSO and
radiotherapy response.
[77, 86–
91, 93, 122,
123, 136,
140, 141]
Development
status Under evaluation + Under evaluation Under evaluation
OS, overall survival; PFS, progression-free survival.
4. RTK Signaling in GBM
Mutations or amplifications of RTK including EGFR,
PDGFRA, basic fibroblast growth factor receptor 1 (FGFR-
1), and insulin-like growth factor receptor (IGFR-1) are
present in more than 80% of primary GBM [28]. These
structurally related proteins coordinate a complex signaling
network that drives and regulates many cellular processes.
In gliomas the two main signaling pathways utilized by
RTK are the RAS/RAF/MAPK pathway that leads to cellular
proliferation, differentiation, and migration and the PI3K/
AKT/mTOR pathway that primarily serves to promote cell
proliferation and survival through progression of the cell
cycle and inhibition of apoptosis [28]. The activity of PI3K
is regulated by the tumor suppressor gene PTEN that is a
negative regulator of this pathway [29]. Loss of PTEN, found
in approximately 36% of gliomas, may result in dramatic
upregulation of this pathway and be a major source of
resistance to EGFR therapies [30].
EGFR mutations, rearrangements, alternative splicing,
and focal amplifications are the most frequent genetic alter-
ations, occurring in nearly 57% of GBM tumors [31]. EGFR
amplification can be found, nearly exclusively, in patients
with a classical subtype of GBM and is very rare in secondary
GBMs [16]. However, the role of EGFR amplification as a
prognostic biomarker has yielded conflicting results. There
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are reports showing no association with overall survival (OS)
in patients, others showing a negative impact, and some
even indicating a favorable impact on patient survival [32–
36]. Unfortunately, despite the high frequency of EGFR gene
amplification, EGFR inhibitors (e.g., gefitinib and erlotinib)
have not been successfully brought into clinical trials for
patients with GBMs [37–39].
The lack of a meaningful response may be due to the rela-
tively poor penetration of these drugs through BBB, acquired
resistance promoting mutations in the targeted RTKs, and
intratumoral heterogeneity in GBM tumors [40, 41]. In
addition, around 50% of patients with EGFR amplification
harbor EGFRvIII mutation, which results from an in-frame
deletion of exons 2–7 and leads to constitutive and ligand
independent receptor activity [42]. However, EGFRvIII prog-
nostic relevance is still controversial, for instance, Shinojima
et al. have shown that EGFRvIII expression in the presence of
EGFR amplification is a strong indicator of poor survival and
prognosis [43]. On the other hand, Montano et al. prospec-
tively analyzed the relationship between EGFRvIII expression
and OS in patients with newly diagnosed GBM treated
with gross total resection and standard radiochemotherapy
(TMZ).Notably in this case, EGFRvIII identified that patients
had significantly longer OS. Furthermore, association of
EGFRvIII/Ki67 of 20% or less, EGFRvIII/normal PTEN,
and EGFRvIII/methylated MGMT allowed identification of
subgroups in GBM patients with better prognosis [44].
Although EGFRvIII seems to be a well-defined drug
target the clinical trials with tumor vaccine rindopepimut
have demonstrated immunologic effect and apparent clinical
benefit only in early phase trials. Tests of this vaccine in
randomized, placebo-controlled phase III studies failed to
show survival benefit [45]. Nevertheless, EGFR still remains
an attractive molecular target and current clinical trials are
focusing on testing new inhibitors that are more potent and
specific to the GBMmutations and introducing mechanism-
based combination therapies [40, 46, 47].
When it comes to other RTK alterations, in a smaller
proportion of secondary GBMs (13%), high-level amplifica-
tion of the PDGFRA has been detected, and nearly half of
these tumors also contained amplification and/or mutation
of EGFR [31, 48]. Despite PDGFRA being strongly associated
with GBM, an anti-PDGFRA therapy using glivec resulted in
only a limited clinical response [49].
Although much less frequent in GBMs, alterations such
as mesenchymal-epithelial transition factor (c-Met) amplifi-
cation and FGFR mutations have been reported in 2% of the
analyzed GBMs [50, 51].
All these activating genetic aberrations can occur simul-
taneously in multiple RTKs within individual GBM and
concurrently express mutations in downstream components
of growth factor receptor pathways. The PI3K/AKT/mTOR,
the most powerful oncogenic pathway in GBM, can be
activated by mutations in either the catalytic (PIK3CA)
or regulatory (PIK3R1) domains of PI3K [52]. The TCGA
study found that almost 10% of the GBMs had mutations
in the PIK3R1, which has not been found to be frequently
expressed in any other cancer [53]. Furthermore, it has
been reported that AKT classification can be a predictive
marker that identifies a subset of GBMpatients responding to
carmustine (BCNU)/CCNU and PI3K/AKT/mTOR pathway
inhibitors [54]. More recent studies have revealed that the
tumor suppressor gene NF1, that encodes neurofibromin
(RAS negative regulator), is mutated/deleted in 15% to 18%
of primary GBMs (mesenchymal subclass) [53, 55].
5. TP53/MDM2/p14ARF Pathway
The TP53 tumor suppressor gene, at chromosome 17q13.1,
encodes a p53 protein that regulates target genes involved
in (i) cell cycle arrest in the G1 and/or G2 phase of cell
cycle, (ii) cell death and differentiation, (iii) DNA repair,
and (iv) neovascularization [56–58]. TP53may be inactivated
indirectly, as a result of mutation or deletion, or directly due
to damage of cooperating genes [59]. MDM2 oncoprotein
negatively regulates p53 activity through the ubiquitination
and proteasomal degradation of p53. In turn, the p14ARF
protein functionally antagonizes MDM2 and, thus, prevents
the silencing of p53 [60]. Initially, TP53 mutations have
been associated with secondary GBMs rather than with
primary (65% versus 28%) [10], but recent TCGA data has
reportedTP53mutations inmany primaryGBMs.Theoverall
frequency of genetic alterations in the TP53/MDM2/p14ARF
pathway was found in 87% of GBMs, in 35% through TP53
mutations or homozygous deletion, in 14% due to MDM2
amplification, and in 49% as a result of p14ARF homozygous
deletion or mutation [53].
6. p16INK4a/CDK4/RB1 Pathway
The RB1 protein controls progression through G1 into the S-
phase of the cell cycle.TheCDKN2A (p16INK4a) protein binds
to CDK4 cyclin and inhibits the CDK4/cyclin D1 complex
that prevents cell cycle transition from G1 to S-phase [61].
Therefore, loss of normal RB1 function may result from
altered expression of any of the p16INK4a, CDK4, or RB1
genes.
Inactivation of this pathway is commonly observed in
both primary and secondary GBMs. While mutations in
RB1 are not common (11%), genes encoding its upstream
regulators are frequently altered, in particular mutations and
deletions of CDKN2A/p16 (52%) and amplification of CDK4
(18%) [62]. Despite frequent occurrence of these defects none
of themhave been identified as a useful prognostic biomarker
in GBMs [63].
7. IDH Mutations
The IDH1 and IDH2 genes encode two critical metabolic
enzymes: isocitrate dehydrogenase 1 (present in the peroxi-
somes and cytosol) and isocitrate dehydrogenase 2 (present in
the mitochondria). These proteins catalyze the oxidative car-
boxylation of isocitrate to alpha-ketoglutarate, which results
in the production of NADPH in the citric acid (Krebs) cycle
[64, 65]. Mutations of these IDH genes promote reactions
that generate the oncometabolite 2-hydroxyglutarate (2-HG)
[66, 67]. In gliomas the most frequent missense mutations in
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IDH genes are present at the 132 residue in IDH1 (85%) and
at 172 in IDH2 (3%) [12, 68]. They have been mainly found
in secondary GBMs (73%–85%), along with grades II and III
astrocytic and oligodendroglial tumors (72–100%) but appear
to be rare or absent in primary GBMs (5%) [12, 69]. Several
studies have reported that the presence of IDH mutations
in diffuse glioma is associated with younger age (mean 32–
47) [12, 70, 71]. Although, IDH-wild-type and IDH-mutant
gliomas are histologically similar, numerous groups have
reported that gliomas harboring IDH mutations represent a
distinct disease entity that arises from a different cell type
and occur in the presence of other genomic abnormalities,
such as TP53 mutation or 1p/19q chromosome deletion,
and happen mutually exclusively in gliomas with EGFR
amplification and chromosome 10 loss [17]. Moreover, IDH-
mutant tumors have also been linked with substantial epi-
genetic changes, such as DNA methylation disorders, which
harbor a striking pattern of hypermethylation of certainDNA
promoter regions termed as glioma-CpG island methylator
phenotype (G-CIMP) [72]. It has been shown that 78% of G-
CIMP+ tumors carry IDH1 mutations [73], and 98% of these
malignancies are positive for IDH2 [74].
The wild-type IDH gliomas including pilocytic astro-
cytomas and primary GBMs are independent of the IDH
pathway (G-CIMP−). Conversely, most grades II and III
gliomas and secondary GBMs share IDH mutations (G-
CIMP+). Up to 87.5% of G-CIMP+ tumors represent a
proneural gene expression subtype and are usually found in
younger patients (mean age at diagnosis: 36 years versus 59
years) [73, 75]. Moreover, they also carry a better prognosis
than the IDH-wild-type gliomas of the same histological
grade [76]. In addition, Beiko et al. demonstrated that IDH1
mutation status is associated with the benefit of surgical
resection in malignant astrocytic gliomas (WHO grades
III and IV). More aggressive resection involving the whole
tumor (both enhancing and nonenhancing part) correlated
with better prognosis in patients with IDH1 mutant GBMs
rather than with wild-type IDH1. In the case of the latter,
no prognostic benefit was observed after the resection of
nonenhancing part [77].
Importantly, since the presence of IDH mutations has
been shown to correlate with better OS and progression-free
survival (PFS) in GBM patients, this aberration became the
only molecular marker included in the updated 2016 WHO
classification of astroglial brain tumors [8, 78]. Furthermore,
it prompted efforts to develop inhibitors of the mutated IDH
protein for therapeutic purposes. So far, these new drugs
have been reported to induce differentiation in preclinical
models, and clinical proof of concept has been achieved
in early phase I trials (NCT02074839 and NCT01915498)
using AG-120 and AG-221 in adults with relapsed or refrac-
tory acute myelogenous leukemia [79–82]. These promising
early results are now driving expansion of these trials into
solid tumors. Phase I dose escalation studies of AG-120 in
patients with IDH-mutated gliomas and other solid tumors
(NCT02073994) and of AG-221 also in patients with IDH-
mutated gliomas (NCT02273739) are now open. Further
work is urgently needed to determine the most appropri-
ate IDH mutation detection technique to facilitate early
identification of patients who may benefit from these novel
therapies. At the moment IDH mutations are evaluated by
immunohistochemistry, standard sequencing, or genotyping
methods. Furthermore, 2-HG level has been noninvasively
assessed in patients with glioma using magnetic resonance
spectroscopy and proved to be a useful biomarker in moni-
toring treatment response [82].
8. MGMT Methylation
Promotor of MGMT encoding 𝑂
6
-methylguanine-DNA
methyltransferase is a DNA repair enzyme which can effec-
tively protect cells against alkylating agents (e.g., TMZ and
CCNU) through preventing G:C→A:T gene mutations [83].
Disorders of MGMT promoter methylation are associated
with transcriptional silencing of the MGMT gene and loss
of MGMT expression that results in decreased DNA repair
and retention of alkyl groups, thereby allowing alkylating
agents to be more effective in patients with MGMT promoter
hypermethylation.
MGMT promoter methylation is more often found in
secondary GBMs than in the lesions they derive from, such
as low-grade gliomas and primary GBMs (75% versus 48%
versus 36%) [11, 84]. Recently, a number of clinical trials have
shown that MGMT methylation corresponds to greater PFS
and OS in patients who are treated with alkylating agents
[83, 85–87]. Therefore, MGMT promoter methylation status
represents one of the most relevant prognostic factors in
GBMs and has been considered as a potent predictor of
response to alkylating agents.
Furthermore, recent prospective randomized trials
(NOA-08), the Nordic trial, and RTOG 0525 have shown
MGMT promoter methylation can also be a useful predictive
biomarker to stratify elderly GBM patients for RT versus
chemotherapy with alkylating agents. Several studies have
demonstrated that patients with tumors with methylated
MGMT promoter had a survival benefit when treated with
TMZ and radiotherapy, compared with those who received
RTonly, whereas patientswithMGMTpromoter-unmethyla-
ted tumors had no survival benefit from chemotherapy,
regardless of whether it was given at diagnosis together with
RT or as a salvage treatment [88–92]. Consequently, it has
been suggested that elderly GBM patients eligible for either
RT or TMZ should undergo MGMT promoter methylation
testing prior to the clinical decision being made. In addition,
MGMT promoter methylation was associated with greater
PFS and improved of OS in patients with recurrent GBMs
(Director trial) [93]. These findings highlight the necessity
for different therapeutic approaches in patients with GBMs
depending on their MGMT status and introducing MGMT
biomarker assessment into routine clinical practice.
9. Immune Checkpoints
In addition tomutations in cell signaling and growthproteins,
part of the aggressive nature of theGBM is related to its ability
to escape immune system surveillance. GBM has established
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amechanismof dampening the immune response by express-
ing immunosuppressive cytokines (e.g., prostaglandin E2 and
transforming growth factor-𝛽) and increasing activation of
T-regulatory cells [94]. This suppressive immune microen-
vironment is manipulated by two important checkpoint
proteins, cytotoxic T-lymphocyte antigen 4 (CTLA-4) and
programmed cell death protein 1 (PD-1) [95]. CTLA-4 is
exclusively upregulated on T cells and negatively regulates
the early stages of T-lymphocyte activation by competing
with the costimulatory molecule CD28 at binding the B7
ligands. In contrast, PD-1 is expressed by B, natural killer
and dendritic cells as well as activatedmonocytes and tumor-
infiltrative macrophages in addition to T cells [96, 97].
Moreover, PD-1 regulates immunity at multiple phases of
the immune response effecting T-lymphocyte activity in the
peripheral tissues [98]. TCGA analysis has reported high
mRNA expression level of PD-L1, a PD-1 ligand, and CTLA-
4 in mesenchymal GBMs suggesting a correlation between
these immune checkpoint proteins and severity of GBM
[99]. Yet, the prognostic value of these immune checkpoints
in GBM is still controversial. Berghoff et al. performed a
study on 117 GBM patient samples and found no correlation
between PD-L1 and survival [100]. Liu et al. have revealed
that PD-L1 can have both a positive and negative effect on
GBM patient survival depending on the glioma subclass, on
expression levels of PD-L1 regulatory molecules, and most
importantly on the cell type that expresses PD-L1 in the
tumor microenvironment [101]. But most current clinical
studies have demonstrated that PD-1 and/or PD-L1 are
immunohistochemically detectable in the majority of GBM
samples and PD-L1 gene expression significantly correlates
with molecular GBM subtypes (mainly mesenchymal) [100].
Additionally, Nduom et al. have shown that PD-L1 in GBM
patients is overexpressed in a small subpopulation, where
higher expression of PD-L1 is correlated with worse outcome
[102].
With the dramatic success of checkpoint inhibitors (e.g.,
nivolumab and ipilimumab targeting PD-1 and CTLA-4,
resp.) in melanoma, brain metastases, and lung and kidney
cancers, hope has increased regarding the potential activity
of these drugs in glioma [103–106]. Multiple clinical trials of
these checkpoint inhibitors in GBMs and recurrent lower-
grade gliomas are currently in progress (e.g., NCT02017717).
These studies will determine whether this approach has
any beneficial effects for these patients. So far, data from
a phase III trial (NCT00045968) using a dendritic cell
vaccine (DCVax-L) has indicated that monitoring CTLA-4
expression may predict survival in GBM patients, indicating
there may be a role for CTLA-4 as a novel biomarker for
treatment response [107, 108]. Furthermore, the RTOG is also
planning a randomized phase II/III trial to test ipilimumab
in combination with TMZ in patients with newly diagnosed
glioblastoma [107]. Taken together, current findings indicate
that the complexity of tumor microenvironment poses a
major challenge to the development of immunotherapy
approaches for GBMs and proper stratification of CTLA-
4/PD-1/PD-L1-positive and negative patients will be impor-
tant criterion for high-quality clinical trials in GBMs.
10. Imaging Biomarkers
The role of histopathology, proteomics, and next-generation
sequencing methods as a standard reference for assessment
of GBM progression is increasingly being challenged. In
addition to invasiveness and sampling bias they do not
address inter- and intratumor heterogeneity. Therefore, in
contrast to conventional evaluation of ex vivo tissue spec-
imens, development of imaging biomarkers for monitoring
tumor response following therapeutic interventions could
greatly improve individual patient management.
Currently there are no clinically approved imaging
biomarkers for GBM. However, advanced functional imag-
ing techniques including diffusion-weighted magnetic reso-
nance imaging (DW-MRI)with apparent diffusion coefficient
(ADC) mapping, dynamic susceptibility-weighted contrast-
enhanced perfusion imaging, MR spectroscopy (MRS), and
positron emission tomography (PET) have recently demon-
strated a great potential for identifying distinct phenotypes
of GBM tumors. While these results are promising, there is a
large variation in sensitivity and specificity reported, which
likely was a result of small sample size in some of these
studies, and differences in acquisition protocols, as well as
reference standards that have been used [109–111].
Nevertheless, several reports have highlighted that utiliz-
ing genomic and imaging datamay improve the selection and
implementation of the appropriate treatment for targeting
the unique biology of GBM tumors and the detection of
early treatment failure. For example, evaluation of 2-hydroxy-
glutarate (2-HG) by proton MRS has been reported to
correlate with the IDH1 or IDH2mutations in the tumor [112]
indicating that upregulated levels of 2-HG in IDH-mutated
gliomas have the potential in the future to provide impor-
tant diagnostic and prognostic information. Additionally,
numerous MRI parameters such as a high ratio of contrast
enhancing tissue to necrotic tissue (≥1), lower ADC values,
increased T2 to contrast enhancing volume, deceased T2
border sharpness, and elevated relative cerebral blood volume
(rCBV) have been reported as being predictive of EGFR
amplification [113–115]. rCBVmeasurements have also shown
to be a good predictive factor for themalignant degeneration-
free survival, PFS, and OS as well as discrimination of tumor
recurrence and nonneoplastic contrast enhancing tissue after
radiotherapy in low-grade gliomas [116, 117].
Furthermore, an increase in tumor blood volume has
been associated with EGFR amplification, PTEN deletion,
and normal unmethylated MGMT [118–120].
Many of these MRI features are also essential in monitor-
ing the clinical effectiveness of treatment regimens. Larsen
et al. reported nearly 100% sensitivity and specificity using
calculated CBV, which is comparable to those achieved
by 18F-fluorodeoxyglucose (18F-FDG) on the same patients
[121]. Besides, tumor ADC value has been shown to be a
useful indicator for predicting response to bevacizumab. For
example, in a large cohort of 97 bevacizumab-treated patients
with recurrent GBM, low ADC was associated with a poor
outcome in post hoc analysis from the multicenter random-
ized, phase II BRAIN study [122]. However, larger studies
are needed for this imaging biomarker to become universally
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accepted. Also, functional diffusion mapping based on ADC
values determined prior to and after radiochemotherapywere
shown to correlate with both survival benefit and longer PFS
in GBM patients [123].
Aside from MRI, a number of PET radiotracers have
been evaluated as potential imaging biomarkers which may
offer additional insight into brain tumor pathophysiology.
Currently, 18F-FDG is the most frequently used PET radi-
oligand, but it has limited capabilities for GBM imaging
due to elevated glucose uptake in the brain compared to
other tissues, which results in low-grade tumors, small
tumors, and tumors with early recurrence remaining unde-
tected. Therefore, for the past few years other PET ligands
have been assessed including radiolabeled amino acids and
their aromatic analogues (e.g., 11C-methionine (11C-MET),
18F-flouroethyltyrosine (18F-FET), and 3,4-dihydroxy-6-18F-
fluoro-L-phenylalanine (18F-FDOPA)), and hypoxia agents
(e.g., 18F-fluoromisonidazole (18F-FMISO)) since they over-
come the limitations of 18F-FDG providing much higher
tumor/background contrast. The amino acid PET tracers
have attracted most of the attention due to the fact they
enter the brain via amino acid transporters allowing visu-
alization of both low- and high-grade gliomas regardless of
integrity of the BBB [124, 125]. Kim et al., have demonstrated
that among several clinical and metabolic factors, 11C-MET
uptake is associated with poorer patient survival indicating
a prognostic value of this tracer in glioma patients [126].
Pauleit et al. found that there is increased 18F-FET uptake
in nonenhancing tumor areas which are difficult to delineate
using MRI [127]. In addition, Fueger et al., have shown that
imaging using 18F-FDOPA could differentiate between low-
and high-grade gliomas and that tracer uptake correlated
with tumor proliferation in newly diagnosed gliomas, but
not in previously treated recurrent tumors [128]. A study of
22 participants with GBM has shown association between
preradiation volume and degree of tumor hypoxia as mea-
sured by 18F-FIMSO and a shorter time to tumor progression
and decreased survival. These promising results indicate
that hypoxia imaging may also serve in the future as an
early biomarker of radiation resistant tumor regions and
provide insight into radiotherapy planning for patients with
GBM [129]. While current data highlights the potential of
molecular imaging biomarkers for the evaluation of treat-
ment response and survival, further prospective studies are
needed to evaluate their clinical impact. What is needed is an
integration of comprehensive genomic information together
with imaging data that will not only strengthen our under-
standing of heterogeneity in GBM’s genetics, metabolomics,
or epigenetics, but also provide an opportunity to identify
robust predictive biomarkers that could improve therapeutic
outcome and minimize drug resistance.
11. Conclusions
Although numerous challenges remain, recently substantial
progress has been made in the molecular characterization of
diffuse gliomas, providing useful insights into the develop-
ment of more effective targeted therapeutics. Even though
some of these therapies, including IDH or RTK pathway
inhibitors, have so far produced limited or no therapeutic
efficacy in phase III trials, our improved understanding
of their mechanisms of action has helped to determine
how to better incorporate their use in existing treatment
paradigms. Importantly, based on the challenges these drugs
have initially presented, innovative clinical trials have been
designed evaluating different therapeutic strategies. The
detailed description of these regimens was beyond the scope
of this review but, as briefly mentioned in each paragraph,
recent clinical reports are very promising. For example, given
the potential to manipulate or enhance the immune system
machinery to attack and kill tumor cells, immunotherapy has
shed new light on and generated a lot of excitement in the
treatment of GBM, especially with clinical trials that are cur-
rently underway. Phase I/II trials testing DCVax-L in patients
with newly diagnosed GBM showed significant increase in
the median life expectancy [6]. Furthermore, clinical trials
based on either retroviral or adenoviral vectors have demon-
strated that the herpes simplex virus-1 thymidine kinase
(HSV1-TK)/ganciclovir (GCV) systemHSV1-TK/GCV is well
tolerated. However, due to immune suppression mechanisms
present in GBMmicroenvironment, the study has not shown
as expected significant therapeutic benefit [130].
Therefore, against this background, there is an urgent
need to incorporate the status of known biomarkers into the
routine clinical practice which may assist not only in patient
selection, but also in the adjustment of treatment schedule
based on the patient-specific biology. The biggest challenge
lies in better understanding of GBM heterogeneity and the
ability to successfully translate the vast amounts of data
generated by large-scale, next-generation sequencing, and
single tumor cell sequencing, as well as genomic and molec-
ular imaging analyses into a clinically applicable format.
Furthermore, appropriate combination of novel targeted and
immunotherapeutic approaches that are biomarker driven
will hopefully improve the management and lead to more
durable responses in GBM patients.
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